Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 85 Published: March 31, 2022 Report Code: GMDGDHC22009IDB

Cognitive Impairment Associated with Schizophrenia (CIAS) pipeline market research report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated with Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated with Schizophrenia (CIAS) and features dormant and discontinued projects.

What are the key targets in the CIAS pipeline market?

The key targets in the CIAS pipeline market are Glutamate Ionotropic Receptor NMDA Type Subunit, Neuronal Acetylcholine Receptor Subunit Alpha 7, Potassium Voltage Gated Channel Subfamily C Member 1, Cholinergic Receptor Muscarinic, Sodium and Chloride Dependent Glycine Transporter 1, 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 5A, Catechol O Methyltransferase, D Amino Acid Oxidase, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA. Glutamate Ionotropic Receptor NMDA Type Subunit has the highest number of pipeline products.

CIAS pipeline market, by target

CIAS pipeline market, by target

For more target insights, download a free report sample

What are the key MoA in the CIAS pipeline market?

The key MoA in the CIAS pipeline market are Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 5A Antagonist, Catechol O Methyltransferase Inhibitor, Cholinergic Receptor Muscarinic Agonist, D Amino Acid Oxidase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist. Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist has the highest number of pipeline products in the CIAS pipeline market.

CIAS pipeline market, by MoA

CIAS pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key RoA in the CIAS pipeline market?

The key RoA in the CIAS pipeline market are Oral and Nasal. Oral has the highest number of pipeline products in the the CIAS pipeline market.

CIAS pipeline market, by RoA

CIAS pipeline market, by RoA

For more RoA insights, download a free report sample

What are the key molecule type in the CIAS pipeline market?

The key molecule type in the CIAS pipeline market are Small Molecule and Synthetic Peptide. Small molecule has the highest number of pipeline products in the CIAS market.

CIAS pipeline market, by molecule type

CIAS pipeline market, by molecule type

For more molecule type insights, download a free report sample

What are the key companies in the CIAS pipeline market?

The key companies in the CIAS pipeline market are Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, and Atai Life Sciences NV. Autifony Therapeutics Ltd has the highest number of pipeline products in the CIAS pipeline market.

CIAS pipeline market, by companies

CIAS pipeline market, by companies

To know more about companies, download a free report sample

Market report overview

Key targets Glutamate Ionotropic Receptor NMDA Type Subunit, Neuronal Acetylcholine Receptor Subunit Alpha 7, Potassium Voltage Gated Channel Subfamily C Member 1, Cholinergic Receptor Muscarinic, Sodium And Chloride Dependent Glycine Transporter 1, 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 5A, Catechol O Methyltransferase, D Amino Acid Oxidase, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA
Key MoA Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 5A Antagonist, Catechol O Methyltransferase Inhibitor, Cholinergic Receptor Muscarinic Agonist, D Amino Acid Oxidase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist
Key RoA Oral and Nasal
Key Molecule Type Small Molecule and Synthetic Peptide
Key companies Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, and Atai Life Sciences NV

 Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Accure Therapeutics SL

Astellas Pharma Inc

AstraZeneca Plc

Atai Life Sciences NV

Autifony Therapeutics Ltd

Biogen Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Coronis NeuroSciences Ltd

Cyclerion Therapeutics Inc

EuMentis Therapeutics Inc

F. Hoffmann-La Roche Ltd

Merck & Co Inc

Monument Therapeutics Ltd

Neurocrine Biosciences Inc

Novartis AG

Pfizer Inc

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Suven Life Sciences Ltd

Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cognitive Impairment Associated With Schizophrenia (CIAS) – Overview

Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cognitive Impairment Associated With Schizophrenia (CIAS) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cognitive Impairment Associated With Schizophrenia (CIAS) – Companies Involved in Therapeutics Development

Accure Therapeutics SL

Astellas Pharma Inc

AstraZeneca Plc

Atai Life Sciences NV

Autifony Therapeutics Ltd

Biogen Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Coronis NeuroSciences Ltd

Cyclerion Therapeutics Inc

EuMentis Therapeutics Inc

F. Hoffmann-La Roche Ltd

Merck & Co Inc

Monument Therapeutics Ltd

Neurocrine Biosciences Inc

Novartis AG

Pfizer Inc

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Suven Life Sciences Ltd

Vanda Pharmaceuticals Inc

Cognitive Impairment Associated With Schizophrenia (CIAS) – Drug Profiles

ACT-02 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ASP-5736 – Drug Profile

Product Description

Mechanism Of Action

AUT-1 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AUT-6 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AUT-9 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AVL-3288 – Drug Profile

Product Description

Mechanism Of Action

basmisanil – Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-425809 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-474121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-955829 – Drug Profile

Product Description

Mechanism Of Action

CAD-8688 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CAD-9303 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CP-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CY-6463 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EM-036 – Drug Profile

Product Description

Mechanism Of Action

luvadaxistat – Drug Profile

Product Description

Mechanism Of Action

History of Events

MK-4334 – Drug Profile

Product Description

Mechanism Of Action

NBI-1065846 – Drug Profile

Product Description

Mechanism Of Action

History of Events

pesampator – Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-03463275 – Drug Profile

Product Description

Mechanism Of Action

RL-007 – Drug Profile

Product Description

Mechanism Of Action

History of Events

samelisant – Drug Profile

Product Description

Mechanism Of Action

History of Events

SKL-20540 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Cognitive Impairment Associated With Schizophrenia – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit COMT for Cognitive Impairment Associated with Schizophrenia (CIAS) and Unspecified Psychiatric Disorders – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Modulate CHRM for Central Nervous System and Respiratory Disorders – Drug Profile

Product Description

Mechanism Of Action

SP-14040 – Drug Profile

Product Description

Mechanism Of Action

SUVND-4010 – Drug Profile

Product Description

Mechanism Of Action

VQW-765 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VU-0467154 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects

Cognitive Impairment Associated With Schizophrenia (CIAS) – Discontinued Products

Cognitive Impairment Associated With Schizophrenia (CIAS) – Product Development Milestones

Featured News & Press Releases

Dec 14, 2021: atai Life Sciences announces successful outcome of phase 2a biomarker trial of RL-007 in cognitive impairment associated with schizophrenia

May 27, 2021: Cyclerion Therapeutics announces publication of CY6463 preclinical data in frontiers in pharmacology

May 24, 2021: Boehringer Ingelheim’s investigational treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation

Apr 27, 2021: Cyclerion Therapeutics hosted webinar to discuss pipeline progress, provides update on CY6463 clinical program

Apr 20, 2021: Cyclerion Therapeutics to host pipeline update webinar

Mar 02, 2021: Neurocrine Biosciences announces top-line results from phase II interact study evaluating Luvadaxistat (NBI-1065844) for the treatment of negative symptoms and cognitive impairment associated with Schizophrenia (CIAS)

Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant

Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia

Apr 17, 2013: SK Biopharma Announces FDA’s Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Accure Therapeutics SL, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Astellas Pharma Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by AstraZeneca Plc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Atai Life Sciences NV, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Autifony Therapeutics Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Biogen Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Boehringer Ingelheim International GmbH, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Bristol-Myers Squibb Co, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Coronis NeuroSciences Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Cyclerion Therapeutics Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by EuMentis Therapeutics Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Merck & Co Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Monument Therapeutics Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Neurocrine Biosciences Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Novartis AG, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Pfizer Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by SK Biopharmaceuticals Co Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Spherium Biomed SL, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Suven Life Sciences Ltd, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Pipeline by Vanda Pharmaceuticals Inc, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects, 2022

Cognitive Impairment Associated With Schizophrenia (CIAS) – Dormant Projects, 2022 (Contd..1)

Cognitive Impairment Associated With Schizophrenia (CIAS) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.